Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,566,239 papers from all fields of science
Search
Sign In
Create Free Account
North Central Cancer Treatment Group
Known as:
NCCTG
A national clinical research group sponsored by the NCI. The research base for NCCTG is located at Mayo Clinic in Rochester, Minn. NCCTG consists of…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.
E. Galanis
,
K. Jaeckle
,
+7 authors
J. Buckner
2010
Corpus ID: 74007973
2018 Background: Angiogenesis inhibition is a promising strategy in GBM treatment. We hypothesized that combination of the anti…
Expand
2010
2010
Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7.
D. Barton
,
Amanda R. Moraska
,
+7 authors
C. Loprinzi
2010
Corpus ID: 68290291
9004 Background: Effective treatments are needed for cancer related fatigue (CRF). Pilot data suggest that methylphenidate may be…
Expand
2010
2010
N0733: Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer.
P. Haluska
,
M. Reinholz
,
+7 authors
E. Perez
2010
Corpus ID: 73884754
TPS129 Background: Insulin-like growth factor (IGF) signaling has been implicated as a mechanism of resistance to therapies…
Expand
Review
2009
Review
2009
PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated…
I. Micallef
,
M. Maurer
,
+7 authors
G. Wiseman
2009
Corpus ID: 78416142
Abstract 137 Background: FDG-PET/CT after 2–4 cycles of chemotherapy has been shown to be predictive of outcome in patients…
Expand
2008
2008
A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study
A. Adjei
,
S. Mandrekar
,
+7 authors
R. Zinner
2008
Corpus ID: 74233468
8080 Background: This phase II study was performed to evaluate the clinical efficacy and toxicity of pem (500 mg/m2 iv) combined…
Expand
2007
2007
N0377: Results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma
R. Rao
,
J. Allred
,
+8 authors
S. Markovic
2007
Corpus ID: 74606828
8530 Background: RAD-001 (Everolimus) is an oral inhibitor of mammalian target of rapamycin (mTOR). Interim analysis results from…
Expand
2005
2005
A pooled analysis of 11 NCCTG advanced stage non-small cell lung cancer (NSCLC) trials reveals the importance of baseline blood counts on clinical outcomes
S. Mandrekar
,
S. Schild
,
+7 authors
J. Jett
2005
Corpus ID: 74448311
7193 Background: An analysis of 11 advanced stage NSCLC trials was performed to examine the impact of several prognostic factors…
Expand
2005
2005
A phase II NCCTG/CALGB trial of imatinib (STI571) in patients (pts) with c-kit-expressing relapsed small cell lung cancer (SCLC)
G. Dy
,
Austin Miller
,
+6 authors
Ncctg Calgb
2005
Corpus ID: 56613094
7048 Background c-Kit over-expression is found in multiple cancers including up to 70% of SCLC. STI571 can inhibit c-kit tyrosine…
Expand
2005
2005
NCCTG 94–72-53: Diagnostic and prognostic significance of 1p and 19q deletions in patients (pts) with low-grade oligodendroglioma and astrocytoma
J. Buckner
,
K. Ballman
,
+7 authors
R. Jenkins
2005
Corpus ID: 78720922
1502 Background: Tumor deletions of chromosomes 1p and 19q are associated with improved prognosis and responsiveness to…
Expand
1990
1990
Evaluating cancer chemotherapy by infusion.
R. Donehower
Journal of the National Cancer Institute
1990
Corpus ID: 42780690
For the vast majority of antineoplastic agents, the optimal schedule of administratio n has not been established. The reasons why…
Expand